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Dry eye syndrome (DES, Keratoconjunctivitis sicca) is a common disorder of the tear ﬁlm caused by decreased tear production or
increased evaporation. Changes in tear composition also promote inﬂammation on the ocular surface by various mechanisms.
Artiﬁcial tear drops, tear retention treatment, stimulation of tear secretion, or anti-inﬂammatory drugs may be used for
dry eye treatment according to the severity of the disease. For untreated patients, the risk of ocular infection increases at
considerable level and clinical course of the disease may proceed up to infection, corneal ulcer, and blindness. Artiﬁcial tears
and/or punctual occlusions are used for tear replacement or preservation. New treatment approaches are designed to modify
the underlying disease process. For the treatment of severe dry eye disease, cyclosporin A (CsA), the ﬁrst one of the new
generation immunomodulatory drugs, which has an anti-inﬂammatory eﬀect, is frequently used. CsA has immunosuppressive
eﬀects following systemic application. Following local administration of CsA, it is expected to obtain eﬀective drug concentration
at the target area and to avoid the various side eﬀects associated with systemic delivery. Microspheres, implants, and liposomes
have been developed for administration of CsA subconjunctivally in order to enhance its eﬃciency.
1.Introduction
According to the the Dry Eye Workshop (DEWS, 2007)
report, prevalence of dry eye ranges from 5–30% in people
aged 50 years and older. Prevalence of DES is estimated that
about 3.2 million women and 1.7 million men, for a total of
4.9 million patients 50 years and older, have dry eye. Tens
of millions more have mild dry eyes that may be notable only
whensomeadversecontributingfactorispresent,suchaslow
humidity or contact lens wear [1, 2] .T h e r ei sa ni n c r e a s eo f
DES prevalance in recent years due to the general aging of
the population as well as the increased use of some certain
drugs [3, 4]. DES is characterized by chronic dryness of the
cornea and conjunctiva which is caused by unstable tear
ﬁlm associated with abnormality of the lipid, protein, and
mucin proﬁles [5]. Changes in tear composition resulting
from lacrimal dysfunction, increased evaporation, and/or
poor clearance have proinﬂammatory eﬀects on the ocular
surface [6].
Typical symptoms of DES include burning, stinging, and
photophobia. In addition, patients with chronic, uncon-
trolleddiseasemaycomplainaboutblurredvision,decreased
ability to produce tear, and intolerance to contact lenses.
Ocular surface abnormalities may develop, including super-
ﬁcial punctate erosions, epithelial defects, corneal ﬁlaments
andinseverecases,cornealulcers[11,12].Asaresultofthese
symptoms, DES can have a considerable impact on visual
function, daily activities, social and physical functioning,
workplace productivity, and quality of life [13].
Although DES can arise from various types of diseases,
common to all is the involvement of immune-mediated or
inﬂammatory-mediated pathways. One of the major causes
of the DES is Sj¨ orgen’s Syndorme which is an autoim-
mune disease usually eﬀecting middle-aged women. It is
believed that progressive lymphocytic inﬁltration is respon-
sible for the destruction of normal secretory function [14–
17]. Dysfunction of the lacrimal functional unit alters the
balance of tear ﬁlm components, which support and protect2 The Scientiﬁc World Journal
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Figure 1: Inﬂammatory mediators in DES. (MMPs: matrix metalloproteinases) [5].
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Figure 2: The structure of CsA [7].
the ocular surface by stabilizing the tear ﬁlm. These changes
in tear composition also induce inﬂammation on the ocular
surface by several mechanisms (Figure 1). Current lack of
understanding makes the diagnosis of DES diﬃcult. Progress
in this area should make it possible to characterize, diagnose,
and treat DES more eﬀectively [18].
Cyclosporine A (CsA) is a neutral, hydrophobic, cyclic
peptide of amino acids which can be isolated from several
speciesoffungi[19].ItsmolecularformulaisC12H111N11O12
and its molecular weight is 1202.64Da. CsA molecule
contains four intramolecular hydrogen bonds that impart
high rigidity to its cyclic structure (Figure 2)[ 20]. This un-
usual structure of CsA confers a very low aqueous solubility,
causing highly variable and incomplete absorption from
its conventional oral or topical formulations. As a result,
an uncertain relation between the drug dosage and in vivo
exposure observed [7].
Numerous reports support that the local immunosup-
p r e s s i o nc a u s e db yC s Ai se ﬀective for the management
of corneal graft rejection, autoimmune uveitis and dry eye
syndrome [21]. It acts as a selective inhibitor of interleukin-
2 (IL-2) release during the activation of T-cells and causes
cell-mediated immune response suppression [22, 23]. CsA’s
mechanism of action is based on its eﬀects on subconjuncti-
val and lacrimal gland inﬂammation, resulting in an increase
in tear production and conjunctival goblet cell density in a
signiﬁcant number of moderate-to-severe DES patients who
received treatment [24, 25]. Topical CsA (Restasis) is cur-
rently the only pharmacologic treatment approved by the US
Food and Drug Administration (FDA) speciﬁcally for DES.The Scientiﬁc World Journal 3
Topical rather than systemic CsA application has been
suggested that could also be therapeutic, without causing
systemic side eﬀects, in the treatment of ocular diseases. This
may be possible because much less of CsA can penetrate into
the bloodstream after its topical application. It is expected
that penetration from an aqueous medium will be even less
than in oil due to its low solubility in water. An ideal topical
formulation to the eye must fulﬁll several requirements as
follows: the formulation must be well tolerated and easy
to administer, increase CsA retention time in the eye, and
avoid systemic absorption. Various ophthalmic formulations
have been developed to improve ocular penetration, reduce
toxicity, and improve tolerability of CsA [26, 27].
2. Treatment of Dry Eye Syndrome(DES)
Commonly used etiologic classiﬁcations (e.g., aqueous-deﬁ-
cient versus evaporative, Sj¨ ogren versus non-Sj¨ ogren) often
are not helpful in establishing a treatment plan for DES.
International Task Force (ITF) guidelines proposing a classi-
ﬁcationofDESseveritybasedonclinicalsignsandsymptoms
were published in 2006. The ITF also developed the treat-
ment algorithms according to classiﬁcation and the presence
of lid margin disease. The ITF treatment recommendations
were based on the severity grading of DES symptoms such
as discomfort, visual symptoms, corneal and conjunctival
staining, lid gland dysfunction, tear break up time, and
Schirmer score [28].
2.1. Tear Substitutes. A wide variety of tear substitutions is
available as over-the-counter (OTC) products. These prod-
ucts diﬀer from the electrolyte composition, osmolarity, vis-
cosity, the presence of preservatives, and compatible solutes
[29].
Preservative-freetearsubstitutesaretheﬁrststepinmed-
ical management of DES [30]. The goal of using tear sub-
stitutes is to increase humidity at the ocular surface and to
improve lubrication [31]. Mild cases of DES, in which there
are no signs of damage to the conjunctiva or cornea, may be
successfully managed with artiﬁcial tears applied up to four
times per day. In moderate cases of DES, examination will
reveal mild damage to the cornea, more frequent treatment
will be required [32].
Short-acting preparations are based on carboxy-methyl-
cellulose (CMC) or polyvinyl alcohol (PVA), whereas longer
acting artiﬁcial tear products contain aqueous carbomer
gels or paraﬃn. A preservative-free 0.5% hydroxypropyl
methylcellulose (HPMC) formula was found to be eﬀective
in improving DES symptoms in both Sj¨ ogren’s Syndrome
(SS) and non-Sj¨ ogren’s Syndrome (non-SS) DES patients,
with a signiﬁcant improvement in conjunctival and corneal
staining scores and breakup times [33].
However, the use of artiﬁcial tears has some limitations.
Natural tears have a complex composition of water, salts,
hydrocarbons, proteins, and lipids that artiﬁcial tears cannot
exactlysubstitute. Formulations containing additional ingre-
dients have been prepared to increase their contact time
with the ocular surface to overcome this problem. These
ingredients are designed to have mucoadhesive properties, as
they adhere to and simulate the mucous layer of the tear ﬁlm
[34, 35]. Ludwig et al. used Slit-lamp ﬂuorophotometry to
evaluate precorneal kinetics of viscous eye drops containing
Carbopol 940, disodium EDTA, and a ﬂuorescent tracer in
humans. The results showed that the ocular retention of
the tracer depends on the concentration of the polymer
instilled and disodium EDTA addition does not improve
the precorneal kinetics signiﬁcantly [36]. Carbopol 940 oph-
thalmic vehicles were prepared by the same group in order
to investigate the interaction between the simulated lacrimal
ﬂuid and the polymer. The inﬂuence of sodium ﬂuorescein
on the physicochemical properties of the polymer vehicles,
was also examined. Four kinds of vehicles containing man-
nitol (5%), sodium ﬂuorescein (0.05%), and disodium
edetate (0.01%) were formulated. Regarding the results,
threeconcentrationsofCarbopol940vehicles(0.20%,0.15%
and 0.10%) were proposed for in vivo evaluation [37].
The rheological behaviours of diﬀerent types of Carbopol
(Carbopol 940, 934, 941, and 910) were also investigated.
The aqueous vehicles of Carbopol 940 were found to show
excellent appearance and clarity when compared with the
o t h e rt y p e so fp o l y m e r[ 38].
Other common additives used in artiﬁcial tear prepa-
rations are buﬀers, which are used to maintain the pH of
humannaturaltears(7.4)ascloselyaspossiblewhentheyare
applied to the eye [34]. In addition, hypotonic electrolyte-
based formulations have been developed based on the
recognition of the importance of tear osmolarity [39].
Autologous serum eye drops, which are produced from
patient’s serum, are also commonly used based on the sever-
ity of dryness and presence of associated ocular surface com-
plications.Ithassimilarbiochemicalandmechanicalproper-
ties, but not identical, to those of normal aqueous tears [40].
Furthermore, the use of serum eye drops implies the risk of
infectious disease transmission from the donor [41].
2.2. Tear Preservation. Occlusion of the lacrimal puncta or
canaliculi is a common nonpharmacological therapy for
DES. The punctal plugs block the ﬂow of the tears through
the canaliculi which connect eyes to the nose. These systems
have been claimed to improve the quantity and the quality
of the aqueous component of the tear ﬁlm, relieving the
symptoms of DES [9, 42].
The decision to block the tear drainage system should
be taken with care because of the potential undesired eﬀects
of the plugs. Delayed tear clearance can result in increased
concentration of proinﬂammatory cytokines in the tear ﬁlm,
causing desensitization of the corneal surface and promoting
inﬂammation. It is also possible that delayed tear clearance
can result in increased toxicity of other ocular medications
that the dry eye patient might use [43, 44].
2.3. Treating the Causes of DES. Topical steroids target the
inﬂammatory component of DES in a nonspeciﬁc manner.
This therapy can be considered as a short-term pulse for the
inﬂammation because of the high risk of complications with
chronic use [45]. When blepharitis is the underlying cause
or a contributory element of dry eye, topical tetracyclines4 The Scientiﬁc World Journal
have become the treatment of choice [32, 46]. It was found
a positive relationship between hormone levels and tear
production in pre- and postmenopausal women and estrogen
levels correlated positively with tear function [47]. It has
been reported that injection of botulinum toxin in the eyelids
produced a decreased lacrimal drainage. The actual clinical
eﬃciency of botulinum toxin injections as a DES treatment
has yet to be evaluated [48].
Topical nonsteroidal anti-inﬂammatory drugs (NSAIDs)
have been used oﬀ-label in DES treatment. There are two
randomized trials with topical diclofenac and topical ketoro-
lac that provide evidence of NSAID eﬃcacy [49, 50]. Oral
pilocarpine has been demonstrated to increase tear produc-
tion and ﬂow, thus it improves the symptoms of DES in
Sj¨ ogren’s syndrome patients [51].
VitaminAeyedropsarealsoeﬀectiveforthetreatmentof
dry eye disorder [52]. An o/w emulsion of 0.01% all-trans-
retinoic acid (tretinoin, vitamin A) was prepared and clini-
cally evaluated in DES patients by Selek et al. It was reported
that tear ﬁlm breakup time was signiﬁcantly improved by
retinoic acid treatment [53, 54]. In another study, poly
(lactic-co-glycolicacid)(PLGA)microspherescontainingall-
trans retinoic acid were prepared. In vitro release studies
showed that retinoic acid release from microspheres lasted
for 11 days [55].
CsA has been successfully used as a systemic immuno-
modulator, motivating extensive research on its mechanisms
of action and formulation alternatives. An FDA-approved
ophthalmic CsA formulation has been available for only a
few years and has been shown to be beneﬁcial in DES. There-
fore, the main focus of this review is the delivery systems
for CsA, which is one of the recent common treatments in
DES.
2.3.1. CsA Delivery Systems for Dry Eye Syndrome (DES)
Treatment. CsA is one of the greatest discoveries in the
history of organ transplantation in the last few decades. In
November 1983, the FDA approved CsA for the prevention
of transplant rejection and complete chemical synthesis of
CsA that was reported by Wenger in 1984 [56, 57].
Topical CsA preparations have been used to treat ocular
surface lymphocyte-driven inﬂammation in animals since
1989 [58]. A commercial product, Optimmune, was ap-
proved in 1996 for canine keratoconjunctivitis sicca [83].
Topical 0.05% CsA has been shown to be an eﬀective ther-
apeutic agent for moderate-to-severe dry eye in phase III
clinical trials and in December 2002, FDA approved CsA
emulsion (RESTASIS) for treating the inﬂammatory compo-
nent of dry eye. This approval represents a major shift in
the treatment of dry eye and in our understanding of its
pathogenesis [5, 24]. Pricing models for topical cyclosporine
for the treatment of refractory moderate-to-severe dry eye
disease are evaluated by Brown et al. [84]. The results indi-
cated that the price of CsA emulsion could be raised 228%
whichmeansthatCsAcostsmuchmorelowerthanitsworth.
Plenty of studies have been made to overcome the dif-
ﬁculties mentioned above, in introduction part, to increase
the therapeutic eﬃcacy of CsA and decrease its side eﬀects
by various approaches such as solid formulations, liposomes,
emulsions and microemulsions, microspheres, nanoparti-
cles, and physical or chemical enhancers (Table 1). Topical,
subconjunctival, and systemic routes have been studied for
CsA delivery for the DES treatment. However, intravitreal
administration is not a preferred administration route in
DES even though it is the usual route for posterior segment
disorder therapy.
(1) Topical Administration
(a) Aqueus Solutions. Various approaches have been studied
to solve CsA’s aqueous solubility problem. Furrer et al. re-
ported that Cremophor and benzalkonium signiﬁcantly
increased ﬂux rates of CsA across cornea while DMSO has
no eﬀect [63]. Benzalkonium is well tolerated at the concen-
tration used in eye drops as preservative (0.01% w/v), but
caused ocular irritation at higher concentration (1% w/v)
[85].Cremophorhasbeenassociatedwithchangesofcorneal
surface structure following topical administration [86].
Cyclodextrins (CDs) are cyclic oligosaccharides that are
capable of forming inclusion complexes with a variety of
guest molecules owing to their special structure, with a hy-
drophilic external surface and a hydrophobic cavity lined
with protons. CDs have the ability to interact with poorly
water-soluble drugs and drug candidates resulting in an in-
crease in the drug’s apparent water solubility and dissolution
rates [87]. It has been reported that solubility of CsA was
found approximately 100-fold higher than for CsA alone
[88]. Mueller [89] showed that CsA bound to CDs resulted
in higher corneal penetration than CsA corn oil solutions.
However, this formulation resulted in a very small reservoir
eﬀect in the cornea, due to the low intrinsic quantity of
drug in the formulation and fast clearance time on the eye
surface.
The eﬀect of other penetration enhancers on the tran-
scorneal permeation of CsA has also been investigated. The
results have indicated that penetration enhancers have seri-
ous limitation of low tolerance of these molecules, due to
their modiﬁcation of corneal properties [64].
It was recently reported that DES can be progressive in
patients treated with artiﬁcial tears alone, whereas topical
anti-inﬂammatory therapy with CsA 0.05% may slow or pre-
vent the disease progression in patients with DES. Large-
scale controlled studies are needed to conﬁrm these ﬁndings
[90].
(b) Oily Solutions and Ointments. Williams et al. reported
that topical CsA in olive oil solution induces a burning sen-
sation and an irritation on the conjunctiva. These side eﬀects
have been attributed to the vehicles used [58]. Patients did
not complain about these side eﬀects after application of a
2% w/w CsA ointment, and ocular examination supported
that there were no signiﬁcant lesions [91].
A marketed ointment formulation for veterinary use,
Optimmune (Schering-Plough, 0.2% CsA ophthalmic oint-
ment), is approved for the treatment of DES and ocular
surface inﬂammatory diseases in dogs. This formulation is
not available for human use because of poor acceptability by
patients [92].The Scientiﬁc World Journal 5
Table 1: Delivery systems developed for CsA delivery to the eye.
Dosage form/pathway Delivery system Advantages Drawbacks Reference
Topical Solutions
Oils High solubilizing CsA
capacity
Poor tolerance unfavorable
partition [58–60]
α-cyclodextrins (α-CD) Enhanced corneal
penetration Repeated administrations [61, 62]
Penetration enhancers Enhanced corneal
penetration Poor tolerance [63, 64]
Topical colloidal carriers
Micelles High corneal
concentrations at 24 hours
Poor tolerance Stability of
micelles [65]
Emulsion negatively
charged
Improvement in dry eye
symptoms FDA approved Ocular burning [24]
Emulsion positively charged
Enhancement of corneal
retention time, high levels
in cornea and conjunctiva
T o l e r a n c et ob ee v a l u a t e d [ 66]
Microemulsions Improvement in dry eye
symptoms FDA approved [67]
PLGA and CD
nanoparticles
Enhanced retention time
and high cellular uptake T o l e r a n c et ob ee v a l u a t e d [ 8]
PACA nanoparticles Improved corneal
absorption Poor tolerance [68]
Chitosan nanoparticles Good tolerance, high
extraocular concentrations Natural origin of chitosan [69, 70]
Liposomes High concentrations Expensive and challenging
manufacturing [66]
Cys-PEG-SA
nanostructured lipid
carriers
High concentrations &SR Tolerance to be evaluated [71]
Topical solid forms
Collagen shields Bandage eﬀect, high levels
in cornea
Patient discomfort No self
application [72, 73]
Collagen shields +
Liposomes
Slow continuous release,
high tissue concentrations
Complex manufacturing
methods [74]
Punctal Plugs
Double eﬀect of both CsA
and the plug extended
r e l e a s eu pt o3m o n t h s
T o l e r a n c et ob ee v a l u a t e d [ 9]
Silicone-hydrogel contact
lenses Controlled release In-vivo release and toxicity
tests are required [10]
Chemically modiﬁed drugs/topical Prodrugs
Good tolerance, soluble in
water, high tear
concentrations
Aqueus Solubility [75–77]
Subconjunctival liquids Microspheres High levels in cornea and
aqueous humor
No beneﬁts compared to
free CsA [78, 79]
Liposomes High levels at four days in
aqueous humor
No beneﬁts compared to
free CsA
[66, 79,
80]
Subkonjunctival/intraocular solid
Forms
Biodegradable implants
Four week therapeutics
levels in vitreous,
prolongation of corneal
graft survival
Implant is free in the
anterior chamber [81]
Nonbiodegradable implants Controlled release Surgical removal is
necessary [82]
(c) Colloidal Carriers
(1) Micelles. Micelles, which are self-assembling nanosized
colloidal particles with a hydrophobic core and hydrophilic
shell, are successfully used as pharmaceutical carriers for
water-insoluble drugs. CsA was solubilized by micelles of the
nonionic surfactant, polyoxyl 40 stearate, at a concentration
of 2% w/v [50]. After a single administration, 60-fold higher
CsA concentration was achieved in the cornea than the 0.1%
w/v CsA castor oil control solution [26]. However, it was also
reported that micelles are often unstable and their shelf life
must be investigated [65].6 The Scientiﬁc World Journal
Emulsions. Results of the early studies conﬁrmed that emul-
sions could be eﬀective topical ophthalmic drug delivery sys-
tems with a potential for sustained drug release. Particularly
oil in water emulsions are useful for he delivery of lipophilic
drugs. RESTASIS (CsA ophthalmic emulsion, 0.05%) has
receivedapprovalfromtheFDAinDecember2002astheﬁrst
therapy for patients with DES [23, 93–95].
With the recent improvements in aseptic processing, and
the availability of new well-tolerated emulsiﬁers such as pol-
ysorbate-80, emulsion technology is currently under evalua-
tion for topical CsA delivery [67].
Liposomes. Liposomes aremembrane-likevesiclesconsisting
of one or more phospholipid bilayers alternating aqueous
or lipophilic compartments, making them potential carriers
for lipophilic drug like CsA. Liposomal technology has been
studied for the ocular delivery of CsA by Milani et al. [66].
However, the large-scale manufacture of sterile liposomes
is expensive and challenging, which make liposomes hard
to apply for CsA ocular delivery. Furthermore, liposomes
have short half life on the corneal surface and relatively poor
stability [96].
Nanoparticles. Nanoparticles have the ability to encapsulate
and protect the drug against chemical and enzymatic degra-
dation, improve patient compliance, and increase corneal
uptake. As a result of corneal uptake of the NPs, cornea acts
like a reservoir and release the drug in a controlled man-
ner. Besides, the burst release would ensure a suﬃcient
drug level just after instillation. However, this approach
still has drawbacks, such as rapid precorneal clearance [97–
99].
Calvo et al. [100] have prepared nanocapsules composed
of an oily phase loaded with CsA (Mygliol) surrounded by
ap o l y - ε-caprolactone (PCL) coat. After topical administra-
tion, these nanocapsules were taken up by corneal epithelial
cells and achieved corneal levels of CsA that were ﬁve times
higher than a 10mg/mL CsA oily solution. However, the
system could not provide signiﬁcant CsA levels at the ocular
mucosa for an extended period of time [101].
The ex vivo corneal absorption of CsA-loaded poly-
isobutylcyanoacrylate (PACA) nanoparticles and nanopar-
ticles in Carbopol gel was evaluated in bovine corneas
[102]. The authorsfoundthat CsA concentrationsin corneas
were signiﬁcantly higher with nanoparticles in gel than
nanoparticles alone and CsA olive oil solution. Evaluation
of the in vivo tolerance and further characterization of these
nanoparticles should be performed for better understanding
the beneﬁts of the system [68].
It has been investigated the potential of chitosan (CS)
nanoparticles for the speciﬁc delivery of CsA to the ocular
mucosa. The results showed that these systems include their
ability to contact intimately with the corneal and conjunc-
tival surfaces, thereby increasing delivery to external ocular
tissues without systemic drug exposure, and to provide
these target tissues with long-term drug levels. However, the
naturalcharacteristicofchitosanlimits thereproducibility of
the system [69].
Aksunguretal.preparedmucoadhesiveCarbopol-coated
nanoparticles using either PLGA or PLGA-Eudragit RL. It
was reported that the PLGA:Eudragit-CsA (75:25) nano-
particles showed signiﬁcantly higher degree of cellular up-
take, tear ﬁlm concentration (Figure 3) of the CsA, and
AUC0 →24 value in comparison with the other formulations
[8].
The conjugate of cysteine-polyethylene glycol monos-
tearate (Cys-PEG-SA) was synthesized and used to compose
the thiolated nanostructured lipid carrier as a potential
nanocarrierforthetopicalocularadministrationofCsA.The
results demonstrated that the thiolated NLC could deliver
high level of CsA into intraocular tissues due to its bioad-
hesive property and sustained release characteristics [71].
(d) Solid Dosage Forms
Collagen Shields and Particles. Collagen-based solid systems
for CsA delivery, such as shields and particles, have been
developed with the purpose of enhancing the contact time of
the drug with the extraocular tissue. However, such a device
ported to be diﬃcult for self-administration by patients [72].
Prodrug Approach. Another strategy to enhance the pene-
tration of the lipophilic CsA through ocular tissues is the
synthesis of a hydrophilic chemically modiﬁed molecule,
which is inactive and able to transform into the active form
within the tissues. It has been demonstrated that repeated
local administrations of a water-soluble CsA prodrug are as
eﬃcient as systemic CsA [75].
In another study, hydroxyl group of the drug has been
modiﬁed in order to improve the hydrophilicity of CsA. The
results showed that the prodrug is a promising candidate in
the topical treatment of dry eye disease and corneal graft
rejection [76].
CsA-Loaded Punctal Plugs and Contact Lenses. Ap u n c t a l
plug that can also release CsA has been developed by Gupta
and Chauhan [9]. Plugs, that were made of Hydroxyl eth-
yl methacrylate (HEMA), ethylene glycol dimethacrylate
(EGDMA), and silicone, all of which are biocompatible, re-
leasedCsAforabout3monthsatzero-orderatarateofabout
3μg/day. Pharmacokinetic models are also developed for
drugdeliveredthroughRestasisandpunctalplugs,andbased
on these models, the predictions were found to be in reason-
able agreement with reported measurements in humans [9].
The punctal plug design is shown in Figure 4.
Peng and Chauhan developed a new delivery system for
CsA delivery for the purpose of DES treatment using Vi-
tamin-E-loaded silicone-hydrogel contact lenses. ACUVUE
OASYS lenses were selected due to the drug release pro-
ﬁles and loaded with Vitamin E. The results showed that
Vitamin-E-loaded lenses can provide CsA release within the
therapeutic window for a period of about a month. The
comparative results for the CsA release proﬁles of lenses that
are pure or Vitamin-E-loaded are given in Figure 5.I ti sa
promising delivery system though that in vivo release and
toxicity studies are required [10].The Scientiﬁc World Journal 7
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Figure 3: (a) Cellular uptake eﬃciency (%) of Nile red labelled NPs, (b) CsA tear ﬁlm concentration after administration of a single topical
dose to rabbits (n = 6) [8]. (P-CsA = PLGA-CsA, P-E-CsA = PLGA:Eudragit-CsA, P-C-CsA = PLGA-Carbopol-CsA.)
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Figure 4: Schematic and image of the drug loaded punctal plug [9].
(2) Subconjunctival Administration. One of the main routes
of administration for ocular therapeutics is the subcon-
junctival pathway. Microspheres and implants have been
developed and tested after subconjunctival administration.
The advantage of this approach is that it may provide high
drug levels for a longer period of time in the extraocular area
and its major disadvantage is its invasiveness. However, the
subconjunctival route is very useful when aqueous humor is
the target and solid forms allow a better controlled release.
(a) Subconjunctival Injection of Microspheres. Harper et al.
prepared microspheres made of 50:50 PLGA and loaded
with CsA for the purpose of maintaining high levels of CsA
in the cornea and aqueous humor. Even the results of the
tissue concentrations after administration were encouraging,
eﬃcacy tests were not performed [78]. Another group stud-
ied with the same type microspheres, but the formulation
did not show signiﬁcant diﬀerences to CsA oil solution even
though the histopathology showed that the local tolerance
has been improved [103].
(b) Subconjunctival Injection of Liposomes. CsA loaded lipo-
some suspension has been prepared and injected subcon-
junctivally in rabbits, however, liposomes could not achieve
a signiﬁcant improvement comparing the tissue concentra-
tions with free CsA. Furthermore, large-scale manufacture
of sterile liposomes is expensive and technically challenging
[79].
(c) Subconjunctival Injection Implants. Biodegradable PLGA
copolymers of composition 85:15 lactide/glycolide was used
to manufacture CsA-loaded implants. The advantage of this
system is that it may provide therapeutic levels of CsA in
about 15 days in the extraocular area, however, it requires
an invasive administration [80].
(3) Systemic Administration
Intravenous Injection. CsA injection is limited due to the risk
of causing anaphylactic shock and nephrotoxicity due to the
solubilising agent Cremophor EL, that was used in the com-
mercial intravenous formulation Cipol [104, 105]. Several
i.v. formulations of CsA such as liposomes, microspheres,
and microemulsions have been investigated to improve the
therapeutic eﬃcacy and remove the need for Cremophor EL
[106]. Intravenous administration of CsA is not a common
way due to the side eﬀects mentioned above.
3. Conclusion
Artiﬁcial tears are the mainstay of DES therapy. Although
artiﬁcial tears can improve DES symptoms of the patients
andthereisnoevidencethattheycanresolvetheDESdepen-
dent inﬂammation; thus, anti-inﬂammatory therapy may
be indicated, including topical corticosteroids, oral tetracy-
clines, and CsA.
Long-term eﬃcacy and safety of topical CsA, in the treat-
ment of DES have been reported in literature. In contrast,8 The Scientiﬁc World Journal
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even topical corticosteroids are eﬀective, they are not recom-
mended for long-term use because of their adverse eﬀects.
Oraltetracyclineshavebeenusedfortheiranti-inﬂammatory
activity. However, this indication is oﬀ-label and is based
on limited evidence. Topical NSAIDs have also been used
oﬀ-label, but whether they have any role in DES has been
questioned due to their side eﬀects in some patients with
compromised ocular surface.
Some of the unfavorable physicochemical properties of
CsA have been improved successfully by enhancing ocular
availability and improving tolerance. However, only a few
formulations of CsA are commercially available and the
extensive literature on the delivery of CsA reﬂects the great
medicalinterestinthischallengingdrug.Consideringtopical
delivery, chitosan nanoparticles, positively charged emul-
sions and CsA prodrugs seem to be the most promising can-
didates. However, none of the described topical systems has
really succeeded in to extend the period of time on the
corneal surface. Therefore, the administration frequency
remainsasaproblemwiththesesystems.CsA-loadedcontact
lenses may be a solution for that problem in case the further
evaluations supports the in vitro results. Furthermore,
sustained therapeutic levels in intraocular tissue can only be
achieved by biodegradable and nonbiodegradable implants.
Diﬀerent formulations may have diﬀerent biological
behaviours, and the choice of formulation may aﬀect both
short- and long-term clinical outcomes. There is still a lack
of clinical comparisons between generic and proprietary
formulations and thus, bioequivalence cannot be assumed.
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